Close

Ocular Therapeutix (OCUL) Tops Q3 EPS by 11c

Go back to Ocular Therapeutix (OCUL) Tops Q3 EPS by 11c

Ocular Therapeutix™ Reports Third Quarter 2016 Financial Results and Provides Corporate Update

November 9, 2016 7:00 AM EST

Preparing to Resubmit NDA for DEXTENZA for the Treatment of Ocular Pain Occurring After Ophthalmic Surgery to FDA by the End of 2016

Began Enrollment in First Phase 3 Clinical Trial with OTX-TP (Sustained Release Travoprost) for the Treatment of Glaucoma and Ocular Hypertension

Entered Into Strategic Collaboration with Regeneron to Develop Sustained Release Formulation of Aflibercept for the Treatment of Wet AMD and Other Serious Retinal Diseases

Conference Call Today at 8:30 am Eastern Time

BEDFORD, Mass.--(BUSINESS WIRE)-- Ocular Therapeutix, Inc. (NASDAQ:... More